PL2852385T3 - Dronedaron do zastosowania w leiszmaniozie, formulacje i połączenia do stosowania w leiszmaniozie - Google Patents

Dronedaron do zastosowania w leiszmaniozie, formulacje i połączenia do stosowania w leiszmaniozie

Info

Publication number
PL2852385T3
PL2852385T3 PL13725136T PL13725136T PL2852385T3 PL 2852385 T3 PL2852385 T3 PL 2852385T3 PL 13725136 T PL13725136 T PL 13725136T PL 13725136 T PL13725136 T PL 13725136T PL 2852385 T3 PL2852385 T3 PL 2852385T3
Authority
PL
Poland
Prior art keywords
leishmaniasis
dronedarone
associations
formulations
Prior art date
Application number
PL13725136T
Other languages
English (en)
Inventor
Stéphane Beilles
Sandra Chambonnet
Jean-Pierre Collaveri
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of PL2852385T3 publication Critical patent/PL2852385T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL13725136T 2012-05-22 2013-05-22 Dronedaron do zastosowania w leiszmaniozie, formulacje i połączenia do stosowania w leiszmaniozie PL2852385T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261650182P 2012-05-22 2012-05-22
EP12306362 2012-10-31
EP12306472 2012-11-28
PCT/EP2013/060513 WO2013182423A1 (en) 2012-05-22 2013-05-22 Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
EP13725136.9A EP2852385B1 (en) 2012-05-22 2013-05-22 Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.

Publications (1)

Publication Number Publication Date
PL2852385T3 true PL2852385T3 (pl) 2020-03-31

Family

ID=49711434

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13725136T PL2852385T3 (pl) 2012-05-22 2013-05-22 Dronedaron do zastosowania w leiszmaniozie, formulacje i połączenia do stosowania w leiszmaniozie

Country Status (15)

Country Link
US (2) US20150150841A1 (pl)
EP (1) EP2852385B1 (pl)
CN (1) CN104487068B (pl)
BR (1) BR112014028706B1 (pl)
CO (1) CO7160058A2 (pl)
CR (1) CR20140526A (pl)
DO (1) DOP2014000257A (pl)
EA (1) EA201492173A1 (pl)
IL (1) IL235752A0 (pl)
IN (1) IN2014KN02584A (pl)
MX (1) MX368416B (pl)
PE (1) PE20150022A1 (pl)
PL (1) PL2852385T3 (pl)
TN (1) TN2014000484A1 (pl)
WO (1) WO2013182423A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110996939A (zh) * 2017-08-03 2020-04-10 诺克斯生物公司 用于治疗皮肤利什曼病的方法的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
DE60117857D1 (de) * 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang

Also Published As

Publication number Publication date
CN104487068B (zh) 2018-09-11
US9700540B2 (en) 2017-07-11
CN104487068A (zh) 2015-04-01
US20150150841A1 (en) 2015-06-04
BR112014028706A2 (pt) 2017-06-27
CR20140526A (es) 2014-12-01
EP2852385B1 (en) 2019-08-21
EA201492173A1 (ru) 2015-04-30
EP2852385A1 (en) 2015-04-01
IL235752A0 (en) 2015-01-29
TN2014000484A1 (en) 2016-03-30
BR112014028706B1 (pt) 2023-01-10
DOP2014000257A (es) 2014-12-15
IN2014KN02584A (pl) 2015-05-08
US20160151326A1 (en) 2016-06-02
PE20150022A1 (es) 2015-02-09
MX368416B (es) 2019-10-02
WO2013182423A1 (en) 2013-12-12
MX2014014258A (es) 2016-04-25
CO7160058A2 (es) 2015-01-15

Similar Documents

Publication Publication Date Title
HRP20190164T1 (hr) Paraziticidni oralni veterinarski sastavi koji obuhvaćaju djelatne tvari sa sustavnim djelovanjem, i načini njihove primjene
ZA201504369B (en) Tetracycline topical formulations, preparation and uses thereof
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
ZA201501541B (en) Supported catalyst and active form thereof, and preparation method and use thereof
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
HK1212625A1 (zh) 用於炎性疾病的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
HK1205166A1 (en) Polymer, composition and use
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
IL251177A0 (en) Parasitic preparations containing benzaimidazole history, methods and uses
HK1189349A1 (en) Formulation comprising crh and alpha-2-macroglobulin crh -2-
EP2837627A4 (en) AMIDOPYRIDINE DERIVATIVE AND USE THEREOF
HK1213142A1 (zh) 分離軸、軸轂組件及其用途
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
HK1209027A1 (en) Vesicular formulations, uses and methods
HK1209026A1 (en) Vesicular formulations, kits and uses
EP2902480A4 (en) PAECILOMYCES VARIOTII VAR. BRUNNEOLUS GPP1101B AND PROCESS FOR PREPARING THE SAME
EP2926811A4 (en) ARTEMISCULAR PHARMACEUTICAL COMPOSITION, MANUFACTURE AND USE
PL2852385T3 (pl) Dronedaron do zastosowania w leiszmaniozie, formulacje i połączenia do stosowania w leiszmaniozie
DK2900234T3 (da) Kræft-kemoterapeutisk middel/formulering, fremstilling og anvendelse deraf
EP2944172A4 (en) AXIS IN TWO PARTS, AXLE-HUB ASSEMBLY AND USE THEREOF
GB201208360D0 (en) Vesicular formulations,kits and uses